Halozyme Therapeutics, INC.: directors' dealings · United States · SEC (Form 4)

About Halozyme Therapeutics, INC.

Halozyme Therapeutics, Inc. is a U.S.-based biotechnology company listed on the Nasdaq in the United States and headquartered in San Diego, California. For international investors, HALO stands out less as a traditional drug developer and more as a drug-delivery technology company. Its core franchise is ENHANZE®, a proprietary platform built around the rHuPH20 enzyme, designed to enable the subcutaneous delivery of injected drugs and fluids. The economic rationale is straightforward: by making administration faster and less burdensome, the technology can improve patient convenience and support broader adoption of partnered therapies. Halozyme therefore occupies a strategic “enablement” position in the pharmaceutical value chain rather than competing purely as a molecule-centric developer. Founded in 1998, the company has spent years building a portfolio of partnerships with leading pharmaceutical and biotechnology groups. Its business model is primarily based on royalty income, collaboration-related payments, and technology commercialization tied to its delivery platforms. That model gives HALO exposure to multiple partner-led product franchises while limiting some of the clinical-development risk typically associated with fully integrated biopharma companies. Halozyme emphasizes the commercial validation of ENHANZE®, which has been used in products approved across more than 100 global markets and has been deployed in multiple launched therapies worldwide. From a competitive standpoint, Halozyme benefits from differentiated intellectual property, a validated delivery platform, and a strong roster of blue-chip partners. Its partners include major global pharma companies, which helps reinforce the credibility and scalability of ENHANZE® across multiple therapeutic areas. The key products and services are centered on facilitating subcutaneous administration of biologics and other injectable therapies, an increasingly important theme in specialty pharma as companies seek to improve patient experience and treatment efficiency. Halozyme has also expanded its technology portfolio through recent acquisitions in formulation and delivery, creating additional long-term licensing opportunities. Geographically, Halozyme remains U.S.-anchored operationally, but its commercial footprint is global through partner networks. Recent corporate milestones include record 2025 results, strong first-quarter 2026 performance, a new $1 billion share repurchase authorization, and continued progress on strategic collaborations and platform expansion. For investors tracking SEC Form 4 insider transactions, HALO is a name where insider activity can be meaningful because the company combines durable royalty generation, visible partner momentum, and ongoing capital-return execution.